Stem Cells Clinical Trial
Official title:
Peripheral Blood Collection of Adult Stem Cells
Verified date | August 2, 2017 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is designed for the collection of stem cells from the bloodstream for use in
research studies. These cells will be studied to determine if they have unique features
particular to the donor that may or may not affect their use for developing new treatments.
Volunteers with or without a blood disease may be eligible to donate stem cells for this
study. Women who are pregnant or breastfeeding may not enroll.
Donors are evaluated with a medical history and physical examination, blood tests and an
ultrasound examination of the spleen. They then undergo stem cell mobilization and apheresis
as follows:
Donors are given injections of a hormone called G-CSF every day for 5 days to stimulate
release of stem cells from the bone marrow into the bloodstream for collection. On the day of
the last injection, donors undergo apheresis to obtain white cells and stem cells. For this
procedure, blood is withdrawn through a catheter (plastic tube) placed in a vein and directed
into a machine where the white cells and stem cells are separated from the rest of the blood
by a spinning process. These cells are extracted and collected in a bag inside the machine,
and the rest of the blood is returned to the donor through a second catheter in a vein in the
other arm. The procedure takes 4 to 5 hours.
Status | Terminated |
Enrollment | 429 |
Est. completion date | August 2, 2017 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
- INCLUSION CRITERIA Ability to give informed consent to participate in the protocol. Meets NIH Department of Transfusion Medicine (DTM) eligibility criteria for blood component donation for in vitro research use (including minimum HCT of 28%, platelet count greater than 50,000/uL). Negative serologic tests for syphilis, hepatitis B and C, HIV, and HTLV-1. Listed below are acceptable medical conditions for inclusion in this protocol. They are derived from donor criteria that pertain to stem cell mobilization and peripheral blood leukapheresis described by the National Marrow Donor Program. Medical conditions that limit bone marrow harvest or re-infusion of cells into stem cell recipients do not apply to this protocol. Age: Volunteers of adult age including those over 60 years old who have no significant cardiovascular disease will be allowed to enroll. Allergies: If volunteers suffer from common allergies to animals, the environment, or medications other than G-CSF, they will be allowed to enroll. Arthritis: In general, if volunteers have mild to moderate osteoarthritis or degenerative arthritis, they will be allowed to enroll. Cancer: If volunteers have a history of cancer or currently have cancer that does not affect their cardiovascular status, they will be allowed to enroll. Mental health conditions: If volunteers have mental health conditions that are well-controlled, they will be allowed to enroll. Diabetes: If volunteers have diabetes, a careful evaluation of their current health status will be necessary. In general, if their diabetes is well-controlled by either diet or oral medications, and have no significant cardiovascular disease, they will be allowed to enroll. EXCLUSION CRITERIA Any concomitant condition or illness that will result in an inability to undergo G-CSF mobilization or apheresis listed below. Allergy to G-CSF or bacterial E. coli products. Autoimmune diseases, such as immune thrombocytopenic purpura, rheumatoid arthritis or systemic lupus erythematosus. Patients with active pulmonary disease. Significant cardiovascular disease or related symptoms such as chest pain, shortness of breath, or uncontrolled hypertension. If volunteers have heart conditions such as well-controlled arrhythmias, or mitral valve prolapse that does not require medication or restrictions, they will be allowed to enroll. If volunteers have elevated blood pressure that is well-controlled by medication or diet and if there is no associated heart disease, they will be allowed to enroll. Epilepsy: If volunteers have had more than one seizure in the past year, they will not be allowed to enroll. If volunteers have well-controlled epilepsy and have had no seizures in the past year, they will be allowed to enroll. Active infections. Pregnant and lactating women. Splenomegaly: Patients having splenic diameters greater than 13.0 cm at the time of initial assessment will be excluded from the protocol. Sickle cell disease. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Bhanu NV, Trice TA, Lee YT, Gantt NM, Oneal P, Schwartz JD, Noel P, Miller JL. A sustained and pancellular reversal of gamma-globin gene silencing in adult human erythroid precursor cells. Blood. 2005 Jan 1;105(1):387-93. Epub 2004 Sep 14. — View Citation
Gershengorn MC, Hardikar AA, Wei C, Geras-Raaka E, Marcus-Samuels B, Raaka BM. Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells. Science. 2004 Dec 24;306(5705):2261-4. Epub 2004 Nov 25. — View Citation
Pomerantz J, Blau HM. Nuclear reprogramming: a key to stem cell function in regenerative medicine. Nat Cell Biol. 2004 Sep;6(9):810-6. Review. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03629015 -
Safety Study of Stemchymal® in Acute Liver Failure
|
Phase 1 | |
Not yet recruiting |
NCT04998461 -
Impact of Obesity, Chronic Kidney Disease and Type 2 Diabetes on Human Urinary Stem Cells
|
||
Completed |
NCT04132531 -
Effect of Weight Loss Surgery on Stem Cells.
|
||
Completed |
NCT03381599 -
Stem Cells After Peripheral Mobilization and Harvest
|
Phase 1 | |
Completed |
NCT02697682 -
Treatment of Osteoarthritis With the Stromal Vascular Fraction of Abdominal Adipose Tissue - a Pilot Study
|
N/A | |
Active, not recruiting |
NCT03874572 -
Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth
|
Phase 1 | |
Not yet recruiting |
NCT03361631 -
Intracavernous Injection of Autologous Mesenchymal Stem Cells in the Treatment of Erectile Dysfunction Resistant to Oral Treatment in Patients With Type I Diabetes
|
Phase 1 | |
Not yet recruiting |
NCT03983902 -
Placental Transfusion Methods and Stem Cells
|
N/A | |
Completed |
NCT06219161 -
The Acute Effect of a Theacrine-based Supplement on Mobilization of Various Stem Cell Populations.
|
N/A | |
Completed |
NCT04713436 -
The Effects of Antibiotic Combinations on Stem Cells
|
||
Active, not recruiting |
NCT03028428 -
Intra-articular Injection of MSCs in Treatment of Knee OA
|
Phase 2 | |
Recruiting |
NCT04646603 -
MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients
|
Phase 2 | |
Withdrawn |
NCT02677350 -
AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE)
|
Phase 1 | |
Completed |
NCT00340392 -
Isolation and Characterization of Mammary Stem Cells
|
N/A |